Matt E. Kalaycio, MD

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalaycm@ccf.org

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalaycm@ccf.org

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.

Matt E. Kalaycio, MD
Director, Leukemia Program, Department of Hematology and Medical Oncology, The Cleveland Clinic

Address: Matt E. Kalaycio, MD, Department of Hematology and Medical Oncology, R35,  Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; kalaycm@ccf.org

Dr. Kalaycio has indicated that he has received grant research support from Sangstat, Novartis, Genta, and Protein Design Labs, and that he is on the speakers bureau of Cell Therapeutics.

This article disscusses therapies that are not yet FDA-approved for the use under discussion and are investigational.